reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | lyophilized form |
| Typical purity | 95 percent or higher by RP-HPLC | value depends on method |
| Storage temperature | minus 20 degrees Celsius or below | desiccated, protected from light |
| Reconstitution solvent | bacteriostatic water | sterile saline also used |
| Primary assay | RP-HPLC with UV detection | often paired with mass spectrometry |
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
On June 28, 2007, the FARC suddenly reported the death of 11 of the 12 kidnapped provincial deputies from Valle del Cauca Department. The Colombian government accused the FARC of executing the hostages and stated that government forces had not made any rescue attempts. FARC claimed that the deaths occurred during a crossfire, after an attack on one of its camps by an "unidentified military group". FARC did not report any other casualties on either side. In 2007, Venezuelan President Hugo Chávez and Colombian Senator Piedad Córdoba were acting as authorised mediators in the ongoing humanitarian exchange between the FARC and the government of Colombia. Colombian President Álvaro Uribe had given Chávez permission to mediate under the conditions that all meetings with the FARC would take place in Venezuela and that Chávez would not contact members of the Colombian military directly but instead would go through proper diplomatic channels. However, President Uribe abruptly terminated Chávez's mediation efforts on November 22, 2007, after Chávez personally contacted General Mario Montoya Uribe, the Commander of the Colombian National Army. In response, Chávez said that he was still willing to mediate, but had withdrawn Venezuela's ambassador to Colombia and placed Colombian-Venezuelan relations "in a freezer". President Uribe responded by accusing Chávez of legitimizing terrorism and pursuing an expansionist project on the continent.
On 20 October 2005, Hoffmann-La Roche decided to license other companies to manufacture Oseltamivir. Also in 2005, Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab, which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. On 22 January 2008, Roche acquired Ventana Medical Systems for $3.4 billion. On 2 January 2009, Roche acquired Memory Pharmaceuticals Corp. On 26 March 2009, Roche acquired Genentech for $46.8 billion. On 12 March 2009, Roche agreed to fully acquire Genentech, in which it had held a majority stake since 1990, after eight months of negotiations. As a result of the Genentech acquisition, Roche moved its Palo Alto–based research facilities to its campus that straddles the border between Clifton, New Jersey and Nutley, New Jersey while Roche's United States headquarters, located on the New Jersey site since 1929, was moved to Genentech's facility in South San Francisco. Genentech became a wholly owned subsidiary group of Roche on 25 March 2009. Roche began vacating the NJ site in 2012, and sold it off in 2016. Roche acquired Medingo Ltd. in April 2010, for $160 million and BioImagene, Inc. in August for $100 million. In 2011, the company received the International Society for Pharmaceutical Engineering Facility of the Year Award for Process Innovation for Roche's "MyDose" Clinical Supply project. In March 2011, Roche acquired PVT Probenverteiltechnik GmbH for up to €85 million.
==== Stepwise coupling and coding ==== One of the most forward-looking method commonly used for DNA-encoding is applied in the synthesis of single-pharmacophore libraries. As the figure shows the library is built repeating the usual cycles of S&P synthesis, The second operation of the cycle is modified: in addition to coupling with the BBs the encoding DNA oligomer is elongated by attaching the code of the BB by ligation.
Sources: en.wikipedia.org
== History == The enzyme classification and nomenclature list was first approved by the International Union of Biochemistry in 1961. Six enzyme classes had been recognized based on the type of chemical reaction catalyzed, including oxidoreductases (EC 1), transferases (EC 2), hydrolases (EC 3), lyases (EC 4), isomerases (EC 5) and ligases (EC 6). However, it became apparent that none of these could describe the important group of enzymes that catalyse the movement of ions or molecules across membranes or their separation within membranes. Several of these involve the hydrolysis of ATP and had been previously classified as ATPases (EC 3.6.3.-), although the hydrolytic reaction is not their primary function. In August 2018, the International Union of Biochemistry and Molecular Biology classified these enzymes under a new enzyme class (EC) of translocases (EC 7).
== January 23, 1982 (Saturday) == In the U.S., the CBS television network broadcast The Uncounted Enemy: A Vietnam Deception, a 90-minute investigative documentary alleging that General William Westmoreland and other officials had suppressed and altered estimates of the actual troop strength of the Viet Cong within South Vietnam during the Vietnam War. U.S. Army Chief of Staff, General William Westmoreland during the war, and commander of U.S. troops in South Vietnam, was accused of manipulating the estimates of the number of communist infiltrators, and would file a $20 million lawsuit for libel on September 13, 1982, against the CBS network, as well as producer George Crile II, narrator Mike Wallace and former CIA analyst Samuel A. Adams. Australian thoroughbred horse trainer Colin Hayes, set a world record as horses he had trained finished in first place in 10 races, seven at Victoria Park in Adelaide and three others at Caulfield race track, on the same day."Big stable in a haze over all that success", by Glenn Lester, The Age (Sydney), January 25, 1982, p. 27 Died: Leonard Sillman, 72, U.S. Broadway theatre producer known for his discovery and introduction of new acting stars, including Henry Fonda, Imogene Coca, and Paul Lynde. Hope Hampton, 84, American opera soprano, silent film actress, and socialite "Hope Hampton, Opera Singer and First-Nighter, Dies at 84", by Joyce Purnick, The New York Times January 24, 1982, p. I-28
Chronic hepatitis B causes liver inflammation and injury that, over several decades, can lead to cirrhosis. Hepatitis D is dependent on the presence of hepatitis B and accelerates cirrhosis in co-infection.
==== Chemotherapy ==== The introduction of nanotechnology into medicine is expected to advance diagnostic cancer imaging and the standards for therapeutic drug design. Nanotechnology may uncover insight about the structure, function and organizational level of the biosystem at the nanoscale. Silver nanoparticles can undergo coating techniques that offer a uniform functionalized surface to which substrates can be added. When the nanoparticle is coated, for example, in silica the surface exists as silicic acid. Substrates can thus be added through stable ether and ester linkages that are not degraded immediately by natural metabolic enzymes. Recent chemotherapeutic applications have designed anti cancer drugs with a photo cleavable linker, such as an ortho-nitrobenzyl bridge, attaching it to the substrate on the nanoparticle surface. The low toxicity nanoparticle complex can remain viable under metabolic attack for the time necessary to be distributed throughout the bodies systems. If a cancerous tumor is being targeted for treatment, ultraviolet light can be introduced over the tumor region. The electromagnetic energy of the light causes the photo responsive linker to break between the drug and the nanoparticle substrate. The drug is now cleaved and released in an unaltered active form to act on the cancerous tumor cells.
Sources: en.wikipedia.org
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.
Most suppliers state a purity of ninety-five percent or higher by reversed-phase chromatography. Values below that threshold indicate a larger proportion of related peptides. The reported figure depends on the detection wavelength, usually 214 nanometers for peptides.
Sealed vials kept cold and dry retain potency for years in many cases. Exposure to warmth or moisture accelerates degradation. A stated expiration date is a supplier estimate rather than a measured endpoint.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.